Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 20348-09-8 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 20348-09-8 ]

CAS No. :	20348-09-8
Formula :	C₇H₆N₂O₂
M.W :	150.14
SMILES Code :	O=C1COC2=CC=CN=C2N1
MDL No. :	MFCD00006697
InChI Key :	ANHQLUBMNSSPBV-UHFFFAOYSA-N
Pubchem ID :	88499

Safety of [ 20348-09-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 20348-09-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.14
Num. rotatable bonds	0
Num. H-bond acceptors	3.0
Num. H-bond donors	1.0
Molar Refractivity	41.06
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	51.22 ?2

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.29
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.14
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-0.16
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.26
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.06
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	0.42

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.26
Solubility	8.2 mg/ml ; 0.0546 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-0.77
Solubility	25.4 mg/ml ; 0.169 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.24
Solubility	0.868 mg/ml ; 0.00578 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-7.12 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.13

Application In Synthesis of [ 20348-09-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 20348-09-8 ]

[ 20348-09-8 ] Synthesis Path-Downstream 1~32

1
[ 20348-09-8 ]
[ 50-00-0 ]
[ 60832-84-0 ]

References: [1]Helvetica Chimica Acta,1976,vol. 59,p. 1593 - 1612.

2
[ 20348-09-8 ]
[ 20348-23-6 ]

Yield	Reaction Conditions	Operation in experiment
85%		a) 3,4-Dihydro-2H-pyrido[3,2-&][l,4]oxazine; To an ice-cold solution of 4H-rhoyrido[3,2-][l,4]oxazin-3-one (5.00 g, 33.3 mmol) in TetaF (40 mL) was added lithium aluminum hydride (66.6 mL of a 1.0 M solution in TetaF, 66.6 mmol). Following the addition, the solution was heated to reflux. After 18 h, the solution was cooled to 00C and quenched the reaction with H2O (4 mL) followed by NaOH (4 mL, 15%) and H2O (10 mL). The resulting slurry was filtered over Celite and the filtrate concentrated to give the title compound (3.87 g, 85%) as a blue-gray powder: 1H NMR (500 MHz, OMSO-d6) delta 7.53 (dd, J= 4.5, 1.0 Hz, IH), 6.90-6.89 (m, IH), 6.61 (br s, IH), 6.44 (dd, J= 8.0, 3.0 Hz, IH), 4.08 (t, J= 4.5 Hz, 2H), 3.39-3.36 (m, 2H); MS (ESI) m/e 31 (M + eta)
79%	With sodium hydroxide; LiAlH4; In tetrahydrofuran;	a) 3,4-Dihydro-2H-pyrido[3,2-b]-1,4-oxazine To a suspension of 2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one (2.0 g, 13.3 mmole) in dry THF (40 mL) was added a solution of LiAlH4 in THF (1.0 M, 26.6 mL, 26.6 mmole) slowly at 0C. After 1 hr the mixture was quenched with 2.0 M NaOH until a solid formed. The mixture was dried (MgSO4), filtered, and concentrated under reduced pressure to give the title compound (1.44 g, 79%) as a white solid which was sufficiently pure for use in the next step: MS (ES) m/e 137 (M + H)+.
	With sodium hydroxide; In tetrahydrofuran; water;	Step 1 Production of 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine Lithium aluminum hydride (2 g) was suspended in tetrahydrofuran (80 mL), and <strong>[20348-09-8]4H-pyrido[3,2-b][1,4]oxazin-3-one</strong> (3.956 g) was added under ice-cooling by small portions. After heating under reflux for 2 hrs, water (2 mL), 15% aqueous sodium hydroxide (2 mL) and water (6 mL) were successively added under ice-cooling, and the mixture was stirred at room temperature. The mixture was dried over anhydrous sodium sulfate. The solvent was evaporated, and the residue was purified by silica gel chromatography (n-hexane-ethyl acetate=1:9) to give the title compound (3.407 g) as a white solid.

		Step 1 Production of 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine Lithium aluminum hydride (2 g) was suspended in tetrahydrofuran (80 mL), and <strong>[20348-09-8]4H-pyrido[3,2-b][1,4]oxazin-3-one</strong> (3.956 g) was added under ice-cooling by small portions. After heating under reflux for 2 hrs, water (2 mL), 15% aqueous sodium hydroxide (2 mL) and water (6 mL) were successively added under ice-cooling, and the mixture was stirred at room temperature. The mixture was dried over anhydrous sodium sulfate. The solvent was evaporated, and the residue was purified by silica gel chromatography (n-hexane-ethyl acetate=1:9) to give the title compound (3.407 g) as a white solid.
		Step 1 Production of 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine Lithium aluminum hydride (2 g) was suspended in tetrahydrofuran (80 mL), and <strong>[20348-09-8]4H-pyrido[3,2-b][1,4]oxazin-3-one</strong> (3.956 g) was added under ice-cooling by small portions. After heating under reflux for 2 hrs, water (2 mL), 15% aqueous sodium hydroxide (2 mL) and water (6 mL) were successively added under ice-cooling, and the mixture was stirred at room temperature. The mixture was dried over anhydrous sodium sulfate. The solvent was evaporated, and the residue was purified by silica gel chromatography (n-hexane-ethyl acetate=1:9) to give the title compound (3.407 g) as a white solid.

References: [1]Patent: WO2007/53131,2007,A2 .Location in patent: Page/Page column 133.
[2]Patent: EP1226138,2004,B1 .
[3]Acta Chemica Scandinavica (1947),1969,vol. 23,p. 2322 - 2324.
[4]Patent: US2008/305169,2008,A1 .
[5]Patent: US2007/10670,2007,A1 .Location in patent: Page/Page column 92.
[6]Patent: US2008/64871,2008,A1 .Location in patent: Page/Page column 56.

3
[ 20348-09-8 ]
[ 34945-68-1 ]

References: [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 1288 - 1296.
[2]Acta Chemica Scandinavica (1947),1971,vol. 25,p. 3135 - 3143.

4
[ 16867-03-1 ]
[ 96-34-4 ]
[ 20348-09-8 ]

References: [1]Acta Chemica Scandinavica (1947),1969,vol. 23,p. 2322 - 2324.

5
[ 16867-03-1 ]
[ 79-04-9 ]
[ 20348-09-8 ]

Yield	Reaction Conditions	Operation in experiment
4.3 g	With sodium hydrogencarbonate; In water; butanone; at 20 - 75℃; for 1.5h;Cooling with ice;	2-Amino-3-ol (45 mmol) and sodium hydrogen carbonate (51 mmol) in water (30 ml) and 2-butanone (30 ml) mixed solution. Under ice-cooling, chloroacetyl chloride (51 mmol) of 2-butanone (10 ml) was slowly added, maintaining the temperature during the addition does not exceed 10 C. It was stirred at room temperature for 30 minutes, stirring for 1 hour at 75 C, and concentrated recrystallization (methanol / water = 1: 1) to give 4.3 g of the title compound.

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 133 - 142.
[2]Helvetica Chimica Acta,1976,vol. 59,p. 1593 - 1612.
[3]Patent: CN103130792,2016,B .Location in patent: Paragraph 0605-0607.

6
[ 20348-09-8 ]
[ 2463-45-8 ]
[ 34950-70-4 ]

References: [1]Acta Chemica Scandinavica (1947),1971,vol. 25,p. 3135 - 3143.

7
[ 20348-09-8 ]
[ 100-39-0 ]
[ 34950-61-3 ]

References: [1]Acta Chemica Scandinavica (1947),1971,vol. 25,p. 3135 - 3143.

8
[ 20348-09-8 ]
[ 109-54-6 ]
[ 34968-17-7 ]

References: [1]Acta Chemica Scandinavica (1947),1971,vol. 25,p. 3135 - 3143.

9
[ 20348-09-8 ]
[ 106-95-6 ]
[ 34968-16-6 ]

References: [1]Acta Chemica Scandinavica (1947),1971,vol. 25,p. 3135 - 3143.

10
[ 20348-09-8 ]
[ 74-88-4 ]
[ 20348-33-8 ]

Yield	Reaction Conditions	Operation in experiment
51%	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 5h;	To a mixture of step-2 Intermediate (0.18 g, 1.20 mmol) and potassium carbonate (0.25 g, 1.8 mmol) in DMF (5 mL) was added methyl iodide (0.11 mL, 1.8 mmol). The resulting mixture was stirred at room temperature for 5 h. The reaction was then diluted with water (10 mL) and the resultant solid obtained was filtered, washed with water (10 mL) and dried to afford 100 mg (51%) of the title compound as white solid. 1HNMR (400 MHz, CDCl3) delta 8.05 (d, J=5.0 Hz, 1H), 7.25 (d, J=8.0 Hz, 1H), 6.96 (d, J=5.0 Hz, 1H), 4.70 (s, 2H), 3.50 (s, 3H); GC-MS (m/z) 164 (M)+.

References: [1]Patent: US2016/145268,2016,A1 .Location in patent: Paragraph 0325.
[2]Acta Chemica Scandinavica (1947),1971,vol. 25,p. 3135 - 3143.

11
[ 93765-25-4 ]
[ 20348-09-8 ]

References: [1]Journal of Heterocyclic Chemistry,1984,vol. 21,p. 1081 - 1086.

12
[ 20348-09-8 ]
[ 40596-44-9 ]
Acetic acid 4-(3-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazin-4-yl)-butyl ester [ No CAS ]

References: [1]Journal of Heterocyclic Chemistry,1996,vol. 33,p. 315 - 318.

13
[ 110-52-1 ]
[ 20348-09-8 ]
[ 204916-44-9 ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 133 - 142.

14
[ 20348-09-8 ]
[ 111-24-0 ]
4-(5-Bromo-pentyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 133 - 142.

15
[ 20348-09-8 ]
[ 65274-89-7 ]
4-{2-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-ethyl}-4H-pyrido[3,2-b][1,4]oxazin-3-one [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 133 - 142.

16
[ 20348-09-8 ]
[ 57061-71-9 ]
4-{2-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-yl]-ethyl}-4H-pyrido[3,2-b][1,4]oxazin-3-one [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 133 - 142.

17
[ 20348-09-8 ]
[ 122450-96-8 ]

Yield	Reaction Conditions	Operation in experiment
76%	With bromine; In N,N-dimethyl-formamide; at 20℃;	To a solution of compound 15 (1 g, 6.66 mmol) in DMF (30 mL) was added dropwise bromine (0.480 mL, 9.32 mmol). The reaction mixture was stirred overnight at room temperature. Water was added and a precipitate was formed which was collected by filtration and dried in lyophilizer overnight to afford title compound 16 (1.16 g, 76% yield). IH NMR <n="95"/>(DMSO-d6) delta (ppm): 11.43 (s, IH), 8.04 (d, J = 2.0 Hz, IH), 7.65 (d, J = 2.0 Hz, IH), 4.67 (s,2H).
69%	With N-Bromosuccinimide; In N,N-dimethyl-formamide; at 20℃; for 72h;	a) 7-Bromo-2H-pyrido[3,2-jb][1 ,4]oxazin-3(4H)-oneA mixture of 2H-pyrido[3,2-d][1 ,4]oxazin-3(4H)-one (1.30 g, 8.66 mmol) and N-bromosuccinimide (1.70 g, 9.53 mmol) in DMF (30 mL) was stirred for three days at room temperature . Water (10 mL) was added and the suspension was cooled EPO <DP n="58"/>with an ice bath. The resulting precipitate was filtered, washed with water, and air- dried in a Buchner funnel to give the title compound (1.37 g, 69%) as a white solid.MS(ES+) m/e 229 [M+H]+.
	With N-Bromosuccinimide; In water; N,N-dimethyl-formamide;	Step 1. 7-Bromo-2H-pyrido[3,2-b]1,4-oxazin-3(4H)-one To a solution of 5.6 g 2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one dissolved in 85 ml of DMF under nitrogen is added 7.96 g NBS in 50 ml of DMF. This is allowed to stir at room temperature overnight. To this is added 35 ml of water and the mixture is chilled The solid material which separates is filtered and washed with 3*100 ml H2 O. This is then dried under vacuum at 70 C. and then used directly in the next step.

	With N-Bromosuccinimide; In water; N,N-dimethyl-formamide;	Step 1. 7-bromo-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one To a solution of 5.6 g 2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one dissolved in 85 ml of DMF under nitrogen is added 7.96 g NBS in 50 ml of DMF. This is allowed to stir at room temperature overnight. To this is added 35 ml of water and chilled. The solid material which separates is filtered and washed with 3*100 ml H2 O. This is then dried in a vac oven at 70 C. and then used directly in the next step.
	With N-Bromosuccinimide; In water; N,N-dimethyl-formamide;	Step 1. 7-Bromo-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one To a solution of 5.6 g <strong>[20348-09-8]2H-pyrido[3,2-b]-1,4-oxazin-3-(4H)-one</strong> dissolved in 85 ml of DMF under nitrogen is added 7.96 g NBS in 50 ml of DMF. This is allowed to stir at room temperature overnight. To this is added 35 ml of water and chilled. The solid material which separates is filtered and washed with 3*100 ml H2 O. This is then dried in a vac oven at 70 C. and then used directly in the next step.
	With bromine; In DMF (N,N-dimethyl-formamide);	In Scheme 90c, the oxazine (24) can be prepared from compound (22) using a similar strategy previously used for (21). Base catalyzed addition of (22) to [CHLOROACETIC] acid followed by cyclization affords intermediate (22). Compound (22) can undergo halogenation using bromine in an aprotic solvent such as DMF to give compound (24).
260 mg	With bromine; In N,N-dimethyl-formamide; at 20℃; for 2h;	the step A compound (3.24mmol) was dissolved in 14 ml of N, N- dimethylformamide, then slowly added Bromine(3.56 mmol). At room temperature it wasstirred for 2 hours then water (300 ml) wasadded .the resulting precipitate was collected by filtration then it was washed with water and dried to give 260 mg ofthe title compound.
65.30 g	With N-Bromosuccinimide; In N,N-dimethyl-formamide; at 50℃; for 20h;	To 2H-pyrido[3,2-b][1 ,4]oxazin-3(4H)-one (45.0 g, 300 mmol) in DMF (360 mL) at 20 C was added NBS (74.7 g, 420 mmol) in one portion, and the resulting brownish suspension was heated at 50 C for 20 hours. The mixture was cooled to 25 C, and the content was poured into stirred water (1 L) in a 3 L flask fitted with an overhead mechanical stirrer. The resulting aqueous suspension was stirred at room temperature for 30 minutes followed by filtration. The yellowish cake was washed with 10% Na2S203 solution (100 mL) followed by water (2 x 100 mL). The cake was aspirated at room temperature under house vacuum overnight. The solids were washed with Et20 (100 mL), aspirated under house vacuum at room temperature for 18 hours, and then dried under high vacuum at 50 C for 72 hours to afford the title compound (65.30 g) as a light tan-colored powdery solid. LC-MS (ES) m/z = 229, 231 [M+H]+. 1H NMR (400 MHz, DMSO-d6): delta 4.68 (s, 2H), 7.66 (d, J = 2.0 Hz, 1 H), 8.02 (d, J = 2.0 Hz, 1 H), 1 1 .44 (br. s., 1 H).

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 133 - 142.
[2]Patent: WO2009/100536,2009,A1 .Location in patent: Page/Page column 93-94.
[3]Patent: WO2006/113432,2006,A2 .Location in patent: Page/Page column 56-57.
[4]Patent: US4906629,1990,A .
[5]Patent: US4822794,1989,A .
[6]Patent: US4866074,1989,A .
[7]Patent: WO2004/14384,2004,A2 .Location in patent: Page/Page column 256; 262.
[8]Patent: CN103130792,2016,B .Location in patent: Paragraph 0608-0610.
[9]Patent: WO2019/49061,2019,A1 .Location in patent: Page/Page column 175.

18
[ 20348-09-8 ]
[ 43219-09-6 ]
4-[2-(4-Phenyl-piperazin-1-yl)-ethyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 133 - 142.

19
[ 20348-09-8 ]
[ 24424-99-5 ]
[ 248263-50-5 ]

References: [1]European Journal of Organic Chemistry,2004,p. 4606 - 4613.
[2]Tetrahedron Letters,1999,vol. 40,p. 6373 - 6376.

20
[ 20348-09-8 ]
[ 100538-35-0 ]
3'-(3-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazin-4-ylmethyl)-biphenyl-2-carboxylic acid [ No CAS ]